Table 2.

Baseline characteristics of patients with GBM treated with nanotherapy in sub-populations of patients suffering from recurrent GBM. KPS before treatment, type of nanoparticles, mode of treatment, and simultaneous treatment therapy for each study are mentioned.

No. of Patients	28	31	7	12	59	6	14	2	Total = 159
Male	20	18	5	7	32	N/A	7	1	Total = 90
Female	8	13	2	5	27	N/A	7	1	Total = 63
Median Age (Range) (in years)	53 (27–68)	50 (21–70)	43 (26–65)	55 (35–73)	55.7	60 (42–75)	2	38.5 (30–47)	Final Median Age = 52.5
Molecular Markers	Multidrug resistance protein 1 (MDR-1) and Multiple resistance protein (MRP)	N/A	N/A	N/A	N/A	MGMT methylation	EGFR expression	Nestin; GFAP; Ki-67; CD133; CD140; TUJ-1	N/A
Induction of Therapy from Diagnosis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	54 weeks for patient 1; 24 weeks for patient 2	N/A
Prior Treatment	Surgery; radiation; chemotherapy	Surgery; radiation; chemotherapy	Surgery; radiation; chemotherapy	Surgery; radiation; chemotherapy	Surgery; radiation; chemotherapy	Not reported	Chemotherapy	Surgery; radiation; chemotherapy	N/A
KPS before Treatment	80	80	80	70	90	N/A	N/A	100	Median = 80
Type of NP	Pegylated Liposome	Pegylated Liposome	Liposome	SPIONs	SPIONs	SPIONs	Minicell (VED Vox) (EnGeneIC)	Liposome (DepCyt)	N/A
Drug Encapsulation/Mode of Treatment	Doxorubicin encapsulation (Caelyx TM, PEG-Dox)	Doxorubicin encapsulation (Caelyx TM, PEG-Dox)	Doxorubicin encapsulation (Caelyx TM)	Intracranial thermotherapy by aminosilane-coated iron oxide NPs	Intratumoral thermotherapy by aminosilane-coated iron oxide NPs	Intracavitary thermotherapy by aminosilane-coated iron oxide NPs	Doxorubicin encapsulation; EGFR targeting via Vectibix	Cytarabine encapsulation-Intraventicular administration	N/A
Simultaneous Standard Therapy	Alone or in combination with tamoxifen	Alone or in combination with temozolomide	None	External beam radiotherapy	External beam radiotherapy	Concurrent, fractionated radiotherapy	None	None	N/A
References	[35]	[34]	[36]	[30]	[31]	[32]	[39]	[37]

N/A is for not available.